Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.38 |
| ▸ | FLT3 | P36888 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1725825 | 1.00 | TDP1 (0.38) | TDP1FLT3KMT2AALDH1A1MEN1 | |
| SCHEMBL1727321 | 0.83 | RECQL (0.34) | FLT3KDM4ERAB9APLAUL3MBTL1 | |
| SCHEMBL13187351 | 0.83 | FLT3 (0.42) | FLT3KDM4ERAB9APLAUL3MBTL1 | |
| SCHEMBL15891095 | 0.83 | FLT3 (0.42) | FLT3KDM4ERAB9APLAUL3MBTL1 | |
| SCHEMBL1727323 | 0.83 | RECQL (0.34) | FLT3KDM4ERAB9APLAUL3MBTL1 | |
| SCHEMBL13187144 | 0.81 | KDM1A (0.36) | TDP1FLT3KDM4ENPC1RAB9A | |
| SCHEMBL15891072 | 0.81 | KDM1A (0.36) | TDP1FLT3KDM4ENPC1RAB9A | |
| SCHEMBL16000800 | 0.80 | TDP1 (0.36) | TDP1KMT2AALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL6719240 | 0.78 | KMT2A (0.38) | TDP1KMT2AALDH1A1MEN1KDM4E | |
| SCHEMBL6719236 | 0.78 | KMT2A (0.38) | TDP1KMT2AALDH1A1MEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2709609-B1 | HETEROCYCLIC COMPOUNDS | SHIONOGI & CO (JP) | 2017-10-04 | — | — | EP | disclosed |
| EP-2709609-B1 | HETEROCYCLIC COMPOUNDS | SHIONOGI & CO (JP) | 2017-10-04 | — | — | EP | disclosed |
| US-9156830-B2 | Heterocyclic compounds | SHIONOGI & CO., LTD. (JP) | 2015-10-13 | — | — | US | disclosed |
| US-9156830-B2 | Heterocyclic compounds | SHIONOGI & CO., LTD. (JP) | 2015-10-13 | — | — | US | disclosed |
| US-9156830-B2 | Heterocyclic compounds | SHIONOGI & CO., LTD. (JP) | 2015-10-13 | — | — | US | disclosed |
| US-20140249159-A1 | HETEROCYCLIC COMPOUNDS | PURDUE PHARMA L.P. | 2014-09-04 | — | — | US | disclosed |
| US-20140249159-A1 | HETEROCYCLIC COMPOUNDS | PURDUE PHARMA L.P. | 2014-09-04 | — | — | US | disclosed |
| US-20140249159-A1 | HETEROCYCLIC COMPOUNDS | PURDUE PHARMA L.P. | 2014-09-04 | — | — | US | disclosed |
| US-8791142-B2 | Oxazole pyridine derivatives useful as S1P1 receptor agonists | MERCK SERONO S.A. (CH) | 2014-07-29 | — | — | US | disclosed |
| WO-2012158844-A1 | HETEROCYCLIC COMPOUNDS | SHIONOGI & CO., LTD. (JP) | 2012-11-22 | — | — | WO | disclosed |
| EP-2403849-A1 | OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS | Merck Serono S.A. (CH) | 2012-01-11 | — | — | EP | disclosed |
| US-20110306636-A1 | OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS | MERCK SERONO SA (CH) | 2011-12-15 | — | — | US | disclosed |
| WO-2010100142-A1 | OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS | MERCK SERONO S.A. (CH) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249159-A1 | HETEROCYCLIC COMPOUNDS | HRH2, UGT1A3, UGT1A1 | TDP1 4608/4885FLT3 4740/4885KMT2A 3048/4885 |
| US-20110306636-A1 | OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS | S1PR1, S1PR3, S1PR5 | TDP1 2717/4885FLT3 734/4885KMT2A 3880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.